Novel Insights and Therapeutics in Multiple Sclerosis

about

(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.

P2860

Q33624245-E0473C2C-DA61-434E-AF26-3E26B7CF3D4C

P2860

Novel Insights and Therapeutics in Multiple Sclerosis

Item

http://www.wikidata.org/entity/Q26784619

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Novel Insights and Therapeutics in Multiple Sclerosis

@ast

Novel Insights and Therapeutics in Multiple Sclerosis

@en

Novel Insights and Therapeutics in Multiple Sclerosis

@nl

type

Item

label

Novel Insights and Therapeutics in Multiple Sclerosis

@ast

Novel Insights and Therapeutics in Multiple Sclerosis

@en

Novel Insights and Therapeutics in Multiple Sclerosis

@nl

prefLabel

Novel Insights and Therapeutics in Multiple Sclerosis

@ast

Novel Insights and Therapeutics in Multiple Sclerosis

@en

Novel Insights and Therapeutics in Multiple Sclerosis

@nl

P1476

Novel Insights and Therapeutics in Multiple Sclerosis

@en

P2093

Catriona A Wagner

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss.

B10 cells: a functionally defined regulatory B cell subset

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

P304

517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.6378.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

F1000 Faculty Rev

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joan Goverman

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281513074

http://www.w3.org/2001/XMLSchema#string

P698

26339480

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4544373

http://www.w3.org/2001/XMLSchema#string

Novel Insights and Therapeutics in Multiple Sclerosis

about

P2860

P2860

Novel Insights and Therapeutics in Multiple Sclerosis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932